As of 2025-06-26, the Intrinsic Value of GT Biopharma Inc (GTBP) is -22.53 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.36 USD, the upside of GT Biopharma Inc is -770.62%.
Based on its market price of 3.36 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 770.62%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -22.53 - -22.53 | -22.53 | -770.62% |
| P/E | (106.45) - (209.47) | (126.41) | -3862.2% |
| DDM - Stable | (35.06) - (100.23) | (67.64) | -2113.2% |
| DDM - Multi | (34.63) - (78.62) | (48.27) | -1536.6% |
| Market Cap (mil) | 8.70 |
| Beta | 0.51 |
| Outstanding shares (mil) | 2.59 |
| Enterprise Value (mil) | 6.34 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.52% |
| Cost of Debt | 5.00% |
| WACC | 7.10% |